NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

The Abstract says:
"A second cohort of patients with rGBM consisted of 8 patients with recurrence following several adjuvant temozolomide treatment cycles. Median OS for these patients is 14.7 months from the time of surgery for first recurrence. The comparator for this cohort is derived from Friedman et al. (2009), who reported mOS of 8.7-9.3 months from the time of first recurrence for rGBM patients treated with Bevacizumab with or without Irinotecan"

There are two errors here.

1. The Median OS for these patients was NOT 14.7 months it was 11 months. -- AVII

The error is on your part. I imagined you were not using a chart that had final events for patients. But then I found this.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018463/

Here is what they had to state about the OS for those 8 patients elsewhere:

For recurrent patients that enrolled in our vaccine trial (n=8), the median overall survival was 17.9 months from the time of initial glioblastoma diagnosis. OS was significantly longer for those who received DC vaccination at initial diagnosis compared to those who enrolled in this trial at the time of recurrence (p=0.03; Supplementary. Fig. 2).

and here:

While the number of glioblastoma patients entered in this Phase I clinical trial was not powered to measure efficacy, the clinical results of this trial are still noteworthy. The median OS from the time of initial surgical diagnosis was 31.4 months for all glioblastoma patients (n=23) treated in this study, including both those enrolled as newly diagnosed and recurrent tumor patients. For those treated in the newly diagnosed setting, the OS was 35.9 months; and the OS was 17.9 months for those who received vaccination at recurrence.

And so, the data in the abstract points out that they enrolled patients who were rapid progression patient. From the 17.9 OS, those patients were enrolled essentially 3.2 months in. True Rapid Progression patients are not chemotherapy responsive. They have the enzyme to correct the damage that chemotherapy does to DNA, and thus not responsive to cytotoxic drug. Rapid progression patients are mostly unmethylated MGMT promoter tumors.

O6-Methylguanine DNA MGMT Promoter

The methylation status of the MGMT promoter has been shown to be a potent prognostic factor in patients with GBM; cells that are deficient in MGMT have shown an increased sensitivity to TMZ. Patients with low MGMT expression (due to methylation of the promoter) benefit more from adjuvant TMZ. Furthermore, patients with methylated MGMT show pseudoprogression more frequently. Until recently, it was not well established whether this latter finding was due to frequent tumor progression immediately after treatment in unmethylated MGMT and, thus, unresponsive tumors or due to a high incidence pseudoprogression as a consequence of higher sensitivity to treatment; we now know it is the latter. MGMT promoter status may predict pseudoprogression in >90% of patients with methylated glioblastoma. An approximately 60% probability of early true tumor progression was observed in unmethylated MGMT promoter tumors.11

The abstract median for the 8-patient is as stated:

Median OS for these patients is 14.7 months from the time of surgery for first recurrence.

The abstract conclusion is real. It is not imagined.

The Abstract conclusion says:
"These results suggest that treatment with DCVax-L can extend survival by 5 months or more in patients with rGBM."

You continue to review the data presented out of the proper context it is put in. And then you run off and make incorrect conclusion. I don't even need to look at your conclusion for the comparison, as I automatically know yours is wrong.

The fact that you continue to accuse reputable investigators of improper conduct after repeatedly being shown you are wrong to me shows how you're not interested in the truth. It also shows your lack of comprehension of the neuro-oncology topic. How you discount and mock 14.7 months extension in survival for rapid progression patients is beyond me. But, we all have our own hobbies.